Julia Hoeng Selected Research

Atherosclerotic Plaque (Atheroma)

10/2021	Impact of whole-body versus nose-only inhalation exposure systems on systemic, respiratory, and cardiovascular endpoints in a 2-month cigarette smoke exposure study in the ApoE-/- mouse model.
1/2020	A 6-month systems toxicology inhalation study in ApoE-/- mice demonstrates reduced cardiovascular effects of E-vapor aerosols compared with cigarette smoke.
4/2019	A six-month systems toxicology inhalation/cessation study in ApoE-/- mice to investigate cardiovascular and respiratory exposure effects of modified risk tobacco products, CHTP 1.2 and THS 2.2, compared with conventional cigarettes.
1/2016	The Apoe(-/-) mouse model: a suitable model to study cardiovascular and respiratory diseases in the context of cigarette smoke exposure and harm reduction.
6/2015	Construction of biological networks from unstructured information based on a semi-automated curation workflow.
6/2014	A vascular biology network model focused on inflammatory processes to investigate atherogenesis and plaque instability.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Julia Hoeng Research Topics

Disease

19	Inflammation (Inflammations) 03/2023 - 04/2013
14	Burns 01/2021 - 01/2016
12	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 01/2014
8	Pneumonia (Pneumonitis) 10/2022 - 06/2015
8	Atherosclerosis 01/2020 - 12/2012
7	Cardiovascular Diseases (Cardiovascular Disease) 12/2020 - 12/2012
7	Lung Diseases (Lung Disease) 01/2020 - 04/2013
6	Neoplasms (Cancer) 06/2023 - 03/2014
6	Atherosclerotic Plaque (Atheroma) 10/2021 - 06/2014
5	Emphysema 01/2021 - 06/2015
4	COVID-19 06/2023 - 01/2021
3	Colitis 03/2023 - 01/2020
3	Multiple Sclerosis 01/2022 - 01/2021
3	Lung Neoplasms (Lung Cancer) 01/2021 - 02/2015
3	Tooth Discoloration 09/2020 - 01/2019
3	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2019 - 11/2014
2	Halitosis 01/2022 - 01/2021
2	Premature Aging 10/2021 - 04/2020
2	Carcinogenesis 01/2020 - 06/2014
2	Mitochondrial Diseases (Mitochondrial Disease) 05/2018 - 10/2016
2	Body Weight (Weight, Body) 01/2015 - 07/2013
1	Tuberous Sclerosis (Bourneville's Disease) 06/2023
1	Myoclonic Epilepsies (Myoclonic Encephalopathy) 06/2023
1	Pain (Aches) 06/2023
1	Seizures (Absence Seizure) 06/2023
1	Lennox Gastaut Syndrome 06/2023
1	Type 2 Diabetes Mellitus (MODY) 06/2023
1	Schizophrenia (Dementia Praecox) 06/2023
1	Treatment-Resistant Schizophrenia 06/2023
1	Parkinson Disease (Parkinson's Disease) 01/2023
1	Cough 01/2023
1	Chronic Cough 01/2023
1	Neuroinflammatory Diseases 01/2023
1	Synucleinopathies 01/2023
1	Human Influenza (Influenza) 10/2022
1	Virus Diseases (Viral Diseases) 03/2022
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022
1	Periodontal Pocket (Periodontal Pockets) 01/2022
1	Thyroiditis 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2022
1	Memory Disorders (Memory Loss) 10/2021
1	Edema (Dropsy) 01/2021
1	Adenoma (Adenomas) 11/2020
1	Carcinoma (Carcinomatosis) 11/2020

Drug/Important Bio-Agent (IBA)

37	SmokeIBA 01/2022 - 10/2011
24	AerosolsIBA 06/2023 - 01/2015
11	Nicotine FDA Link 03/2023 - 01/2015
10	Apolipoproteins E (ApoE)IBA 01/2021 - 12/2012
9	metariboadenosine triphosphorousIBA 11/2020 - 01/2016
7	LipidsIBA 01/2020 - 12/2012
5	AlkaloidsIBA 03/2023 - 12/2019
5	CarbonIBA 01/2021 - 05/2018
5	ApolipoproteinsIBA 12/2020 - 06/2015
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2015
4	anatabineIBA 01/2022 - 01/2020
4	salicylhydroxamic acid (SHAM)IBA 01/2021 - 06/2014
4	XenobioticsIBA 11/2020 - 10/2011
3	CytokinesIBA 01/2021 - 01/2020
3	CeramidesIBA 12/2020 - 12/2012
3	InterleukinsIBA 12/2020 - 07/2015
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2015
3	Lipoproteins (Lipoprotein)IBA 01/2016 - 12/2012
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2023 - 01/2023
2	CarrageenanIBA 03/2022 - 01/2021
2	Chloroquine (Aralen)FDA LinkGeneric 01/2022 - 01/2022
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2022 - 01/2022
2	ProteomeIBA 10/2021 - 10/2015
2	LipopolysaccharidesIBA 01/2021 - 01/2021
2	Composite ResinsIBA 10/2019 - 01/2019
2	GoldIBA 01/2017 - 09/2016
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 09/2016 - 12/2012
2	MicroRNAs (MicroRNA)IBA 06/2014 - 04/2013
1	Analgesics (Analgesic Drugs)IBA 06/2023
1	CannabidiolIBA 06/2023
1	SolutionsIBA 06/2023
1	Clozapine (Clozaril)FDA LinkGeneric 06/2023
1	EnzymesIBA 06/2023
1	Antipsychotic Agents (Antipsychotics)IBA 06/2023
1	NucleotidesIBA 03/2023
1	alpha-SynucleinIBA 01/2023
1	Antitussive Agents (Antitussives)FDA Link 01/2023
1	Codeine (Codeine Phosphate)FDA LinkGeneric 01/2023
1	Narcotics (Narcotic Analgesics)IBA 01/2023
1	Neuroprotective AgentsIBA 01/2023
1	SaltsIBA 10/2022
1	Nasal SpraysIBA 03/2022
1	Sulfur Compounds (Compounds, Sulfur)IBA 01/2022
1	CotinineIBA 10/2021
1	Scopolamine (Hyoscine)FDA Link 10/2021
1	Triglycerides (Triacylglycerol)IBA 10/2021
1	remdesivirIBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	ChemokinesIBA 01/2021
1	Nelfinavir (Viracept)FDA Link 01/2021
1	Raloxifene Hydrochloride (Evista)FDA Link 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2020
1	Particulate MatterIBA 09/2020

Therapy/Procedure

3	Therapeutics 06/2023 - 04/2013